Search
Bivalirudin
go.drugbank.com/drugs/DB00006ApprovedInvestigationalOnce bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. … Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.
Products: BIVACARD 250 MG IV ENJEKSIYON VE INFÜZYON IÇIN LIYOFILIZE TOZ IÇEREN FLAKON, 1 ADETFluvoxamine
go.drugbank.com/drugs/DB00176ApprovedInvestigationalThough it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. … It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeOctreotide
go.drugbank.com/drugs/DB00104ApprovedInvestigationalOn June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance treatment of acromegaly. … [L14501] Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone.
Categories: Somatostatin Receptor AgonistsProducts: SANDOSTATIN LAR 10 MG ENJEKSİYONLUK SÜSPANSİYON İÇİN TOZ VE ÇÖZÜCÜ, 1 ADET, SANDOSTATIN LAR 20 MG ENJEKSİYONLUK SÜSPANSİYON İÇİN TOZ VE ÇÖZÜCÜ, 1 ADETPhylloquinone
go.drugbank.com/drugs/DB01022ApprovedInvestigational[A234264,A234195,A234259] It is indicated in the treatment of coagulation disorders due to faulty formation of coagulation factors II, VII, IX, and X caused by deficiency or interference in the activity … [L33319] Phylloquinone has been synthesized since at least 1939,[A234384] and was approved by the FDA prior to 1955.[L33389]
Synonyms: 2-Methyl-3-[(2E)-3,7,11,15-tetramethyl-2-hexadecenyl]naphthoquinoneEflornithine
go.drugbank.com/drugs/DB06243ApprovedInvestigationalWithdrawn[A262823,L49318] Subsequently, on December 14, 2023, the FDA approved eflornithine again but under the brand name IWILFIN as an oral maintenance therapy to reduce the risk of relapse in adult and pediatric … [A262839] In 1960 and 2000, the FDA approved eflornithine under the brand names ORNIDYL and VANIQUA for the treatment of African trypanosomiasis and hirsutism, respectively, but has since been discontinued
Florbetapir F-18
go.drugbank.com/drugs/DB09149ApprovedInvestigationalFlorbetapir (18F) is a radiopharmaceutical compound containing the radionuclide fluorine-18 bound to the compound florbetapir, a molecule that binds with high affinity to beta amyloid plaque, a peptide … The radionucleide fluorine-18 was chosen as it has a half life of 110 minutes allowing it to accumulate sufficiently in the brain before undergoing positon emission decay.
Synonyms: 4-{(E)-2-[6-(2-{2-[2-(18F)fluoroethoxy]ethoxy}ethoxy)pyridin-3-yl]ethenyl}-N-methylanilineRanibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigationalIn order to improve drug delivery to the target organ, ranibizumab is available for intravitreal use. … [A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO.
Linaclotide
go.drugbank.com/drugs/DB08890ApprovedInvestigationalLinaclotide works to improve the symptoms of constipation and gastrointestinal symptoms of conditions involving constipation.[A260286] … [A260286] Linaclotide is used for the treatment of various types of constipation, including irritable bowel syndrome with constipation. Linaclotide was first approved by the FDA on August 30, 2012.
Rescinnamine
go.drugbank.com/drugs/DB01180ApprovedRescinnamine is an angiotensin-converting enzyme inhibitor used as an antihypertensive drug. It is an alkaloid obtained from Rauwolfia serpentina and other species of Rauwolfia.
Synonyms: Trimethoxy cinnamoyl reserpate de methylCategories: Agents Acting on the Renin-Angiotensin SystemSecukinumab
go.drugbank.com/drugs/DB09029ApprovedInvestigational[L39600] By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. … [A249840] Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015).